The collaboration agreement between the U.S.-based company Performance Medical Technology (PMT) and the University of Trieste was signed at the Palazzo della Regione, with the involvement of the Central Health Directorate of the Regional Administration.

"The agreement involves three departments of the University of Trieste (Department of Life Sciences; Department of Chemical and Pharmaceutical Sciences; Department of Medical, Surgical and Health Sciences), which will conduct research, analysis, and pilot clinical studies aimed at developing a new drug for Parkinson’s disease,” explained the Rector of the University of Trieste, Roberto Di Lenarda. “The scientific activities carried out at the University, in collaboration with PMT (Performance Medical Technologies), will serve as the foundation for the NDA (New Drug Application) required for the drug’s commercialization. We are at the beginning of a stimulating scientific challenge with great social impact, which we will pursue using the skills and outstanding facilities at our disposal.”

The agreement paves the way for PMT’s establishment in the Friuli Venezia Giulia region. Headquartered in Charlottesville, Virginia, PMT specializes in developing new therapeutic options for neurodegenerative diseases—particularly early-stage Parkinson’s—and will launch a series of joint activities in the field of medical research.